Purchase this article with an account.
E.L. Thomas, D.S. Boyer, R.L. Novack, T.G. Chu, R.P. Gallemore, F.M. Rahhal; Ubiquity of Vascular Endothelial Growth Factor in Retinal Diseases Based on Positive Clinical Responses to Intravitreous Bevacizumab . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5650.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy of intravitreous bevacizumab (BV) blockade of vascular endothelial growth factor (VEGF) in 300 eyes of patients with retinal diseases unresponsive to current therapeutic modalities.
Patients with macular degeneration (62%), central and branch retinal vein occlusion (22%) diabetic retinopathy (proliferative and non–proliferative) (12%) and other complex retinal diseases including those less than 4% (neovascular glaucoma, perifoveal telangiectasia, non–clearing vitreous hemorrhage (diabetic and non–diabetic), central serous retinopathy, non–arteritic ischemic optic neuropathy, ocular sarcoid) were treated with a single intravitreous dose (0.05 ml/1.25 mg) of BV. Clinical improvement determined by better visual acuities (VA), reduction in fluorescein angiographic (FA) abnormalities or reductions in retinal anatomic abnormalities by optical coherence tomography (OCT) were evaluated at 1 week and 1 month.
More than 92% of the eyes studied in the retrospective review of treated eyes demonstrated at least 2 of 3 parameters (VA, FA or OCT) for clinical improvement within 1 month of injection. Representative VAs, FAs and OCTs will be presented.
VEGF appears to be ubiquitous as a final common pathway in many retinal diseases and blockade by a specific intravitreous monoclonal antibody (BV) to VEGF has demonstrated potential for therapeutic intervention in multiple retinal diseases when there are no other treatment modalities or they have failed.
This PDF is available to Subscribers Only